InflaRx N.V. IFRX
Biotechnology: Pharmaceutical Preparations · IPO 2017 · data as of November 13, 2026
InflaRx N.V. (IFRX) is a healthcare company listed in the US with a market value of about $172M. In fiscal year 2025 it had revenue of $34464 and net income of -$54M, a net margin of -155582.1%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -677%.
About InflaRx
InflaRx is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2017. It was profitable in 0 of the last 10 years in our data.
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $34464 | $172238 | $69713 | -$34M | — | — | — | -$43M | -$23M | -$7M |
| Net income | -$54M | -$48M | -$47M | -$31M | -$52M | -$42M | -$60M | -$34M | -$29M | -$9M |
| Free cash flow | -$42M | -$50M | -$42M | -$36M | -$45M | -$45M | — | — | — | — |
| EPS (diluted) | $-0.36 | $-0.32 | $-0.32 | $-0.21 | $-0.35 | $-0.28 | $-0.41 | $-0.23 | $-0.20 | $-0.06 |
| Net margin | -155600.0% | -27785.0% | -67630.7% | 91.5% | — | — | — | 79.5% | 124.6% | 129.7% |
| ROIC | -502.5% | -489.0% | -480.6% | -350.9% | -1561.7% | — | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does InflaRx pay a dividend?
Not currently.
Is InflaRx a good stock to buy?
We do not give buy or sell advice. InflaRx scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.